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Abstract 
Background: The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators 
to implement novel clinical trials which combine immunotherapy with different treatment modalities. Moreover is 
also important to investigate the mechanisms which regulate the dynamic expression of PD-L1 on tumor cells and 
PD-1 on T cells in order to identify predictive biomarkers of response. COX-2 is currently investigated as a major player 
of tumor progression in several type of malignancies including melanoma. In the present study we investigated the 
potential relationship between COX-2 and PD-L1 expression in melanoma.
Methods: Tumor samples obtained from primary melanoma lesions and not matched lymph node metastases were 
analyzed for both PD-L1 and COX-2 expression by IHC analysis. Status of BRAF and NRAS mutations was analyzed by 
sequencing and PCR. Co-localization of PD-L1 and COX-2 expression was analyzed by double fluorescence staining. 
Lastly the BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cell lines were used to evaluate the effect of COX-2 inhi-
bition by celecoxib on expression of PD-L1 in vitro.
Results: BRAFV600E/V600K and NRASQ61R/Q61L were detected in 57.8 and 8.9% of the metastatic lesions, and in 65.9 
and 6.8% of the primary tumors, respectively. PD-L1 and COX-2 expression were heterogeneously expressed in both 
primary melanoma lesions and not matched lymph node metastases. A significantly lower number of PD-L1 negative 
lesions was found in primary tumors as compared to not matched metastatic lesions (P = 0.002). COX-2 expression 
significantly correlated with PD-L1 expression in both primary (P = 0.001) and not matched metastatic (P = 0.048) 
lesions. Furthermore, in melanoma tumors, cancer cells expressing a higher levels of COX-2 also co-expressed a 
higher level of PD-L1. Lastly, inhibition of COX-2 activity by celecoxib down-regulated the expression of PD-L1 in both 
BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cell lines.
Conclusions: COX-2 expression correlates with and modulates PD-L1 expression in melanoma cells. These findings 
have clinical relevance since they provide a rationale to implement novel clinical trials to test COX-2 inhibition as a 
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Background
The recent introduction of new and more effective thera-
pies, including treatments based on the stimulation of 
immune response and targeted therapies, has partially 
changed the prognosis of metastatic melanoma patients 
[1]. The more effective therapeutic strategies are based 
on tyrosine kinase inhibitors, such as vemurafenib, dab-
rafenib and trametinib or inhibitors of the immune 
checkpoint molecules Cytotoxic T lymphocyte antigen 4 
(CTLA-4), Programmed death receptor 1 (PD-1) and its 
ligand PD-L1 [2–6].
The immune system plays an important role in eradi-
cating melanoma cells. PD-1 is a T cell co-inhibitory 
receptor with ligand specificity for both PD-L1 and 
PD-L2. PD-L1 results to be expressed in various types of 
cells, including placenta, pancreatic islet cells, mesenchy-
mal stem cells and immune cells. However many human 
cancers, including melanoma, breast, lung, stomach, 
pancreatic, kidney and ovarian carcinoma are shown to 
express PD-L1 and in melanoma, its expression corre-
lates with a poor prognosis [7–12]. Interaction of PD-1 
with PD-L1 (B7-H1) or PD-L2 (B7-DC) represents one of 
the major mechanisms of tumor immune escape [13]. It 
promotes T-cell tolerance and avoids T cell cytolysis of 
cancer cells.
Several mechanisms have been implicated in the regu-
lation of PD-L1 expression by cancer cells such as acti-
vation of mitogenic and pro-survival pathways including 
MAPK and PI3K/AKT, increased activity of transcrip-
tional factors HIF-1, STAT-3 and NF-κB, and presence of 
epigenetic modulators including miR-513, miR-570, miR-
34a, miR-200 and miR-197 [14].
Cyclooxygenases (COXs) are enzymes which catalyze 
the first rate-limiting step in the conversion of arachi-
donic acid to prostaglandins. Two COX isoenzymes have 
been identified: COX-1 is constitutively expressed in 
most tissues and mediates the synthesis of prostaglandins 
in normal physiological processes, whereas COX-2 is not 
detectable in most normal tissues but is rapidly induced 
by various stimuli such as inflammatory reactions [15]. 
COX-2 is also expressed in various tumor types and its 
level correlates with invasiveness and prognosis in many 
tumor entities, suggesting an important role of COX-2 
in tumor development and progression [16]. Epidemio-
logical studies showed that prolonged COX-2 inhibition 
through acetylsalicylic acid or other non-steroidal anti-
inflammatory drugs (NSAIDs) might offer some protec-
tion against colon cancer and some other malignancies 
[17–19]. Moreover, a potential role of COX-2 in mela-
noma development is also not unlikely, since COX-2 is 
frequently expressed in malignant melanomas [20] and 
its inhibition may prevent melanoma progression [21]. 
Evidences available in the literature have shown that 
COX-2 can modulate PD-L1 expression in breast cancer 
cells [22] and its inhibition by the selective COX-2 inhibi-
tor celecoxib enhances the effects of cytotoxic T lympho-
cyte (CTL) function by PD-L1 blocking in chronic viral 
infections [23].
In this study we tested whether COX-2 expression 
correlates with PD-L1 expression in primary and not 
matched metastatic melanoma tumors as well as whether 
COX-2 activity regulates PD-L1 expression in melanoma 
cells.
Methods
Chemical reagents and antibodies
COX-2-specific mouse monoclonal antibody (mAb) 
(clone CX-294), mouse IgG2a, rabbit IgG, the peroxidase 
blocking reagent goat anti-rabbit +  horseradish peroxi-
dase (HRP) visualization reagent, DAB substrate buffer, 
DAB chromogen, bond wash solution, hematoxylin and 
EnVision FLEX +  rabbit linker kitwere purchased from 
DAKO. PD-L1-specific rabbit mAb (clone SP-142) was 
purchased from Spring Bioscience. Cell Conditioning 
Solution was purchased from Ventana medical Systems. 
Protein serum block, steady plus 3,3′-diaminobenzidine 
(DAB) kits, goat anti-mouse IgG dylight 488 and goat 
anti-rabbit IgG dylight 594 were purchased from Abcam. 
Bond primary antibody diluents and 4′,6′-diamidino-
2-phenylindole (DAPI) were purchased from Leica bio-
systems. MACH 2 DOUBLE STAIN 2 and vulcan fast 
red chromogen Kit 2 were purchased from Biocare. The 
COX-2 inhibitor, celecoxib was purchased from Selleck 
Chemicals LLC. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazoliumbromide (MTT) and trypan blue were pur-
chased from Sigma. GAPDH-, Bcl-2- and β-actin specific 
mAbs were purchased from Cell Signaling Technology. 
R-phycoerythrin(PE)-conjugated PD-L1-specific mouse 
mAb [clone MIH1 (RUO)] and PE-conjugated mouse 
IgG1 were purchased from BD Biosciences.
potential treatment to prevent melanoma progression and immune evasion as well as to enhance the anti-tumor 
activity of PD-1/PD-L1 based immunotherapy for the treatment of melanoma patients with or without BRAF/NRAS 
mutations.
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Tumor samples
Primary melanoma tumor biopsies from treatment 
naïve patients and not matched lymph node melanoma 
tumor biopsies from metastatic patients were obtained 
from the tissue bank at Istituto Nazionale Tumori Fon-
dazione “G. Pascale” (Naples, Italy). All samples were 
from Caucasian patients. Patients were consented for 
tissue acquisition per institutional review board (IRB)-
approved protocol. Presence of tumor cells in formalin-
fixed paraffin embedded (FFPE) tissues was monitored 
by hematoxylin and eosin (H&E) staining. All samples 
were reviewed by two experienced pathologists (GB and 
AA) according to American Joint Committee on Can-
cer (AJCC) classification criteria, using standard tissue 
sections and appropriate immunohistochemical (IHC) 
analyses.
Genotyping of metastatic lymph node melanoma tumors
Genomic DNA was isolated from FFPE tumor tissues, 
using the QIAamp DNA FFPE tissue kit (QIAGEN Inc; 
Milan, Italy). The full coding sequences and splice junc-
tions of NRAS (exons 1 and 2) and the entire sequence of 
the BRAF (exon 15) [24, 25] were screened for mutations. 
All samples were assessed for the quality of the puri-
fied DNA, in order to avoid that discrepant case could 
arise from insufficient sample quality. Primer sets were 
designed as described [26]. Sequencing and PCR assay 
were performed as described [26].
IHC analysis
FFPE tumor tissue sections of 3–4 μm thickness were cut 
onto adesive slides, baked at 70 °C (dry heat) for 1 hour 
(h) less than 1  week before use, deparaffinized in four 
changes of 100% xylene, and rehydrated with a graded 
ethanol series (100, 70, 40%) to distilled water. COX-2 
IHC staining was performed using COX-2-specific mAb 
(clone CX-294) and EnVision FLEX utilizing the auto-
mated DAKO Omnis platform. For PD-L1 staining, 
prepared slides were incubated for 12  minutes (min) at 
110 °C in Cell Conditioning Solution, using a commercial 
steamer as the heat source (Biocare Medical, Decloak-
ing Chamber DC12). After cooling for 20  min, PD-L1 
staining was performed using an automated IHC stain-
ing platform (DAKO autostainer Link48). This procedure 
was carried out at room temperature (RT). Following a 
5 min incubation with a peroxidase blocking reagent and 
a 5 min incubation with a protein serum block (1% goat 
serum, 4% BSA in PBS, slides were incubated with the 
PD-L1-specific mAb (clone SP-142) at a concentration of 
3.75 μg/mL in the primary antibody diluents for 90 min. 
The goat anti-rabbit + HRP visualization reagent, which 
is biotin-independent and reduces the potential for back-
ground or nonspecific staining from endogenous biotin, 
was used for PD-L1-specific antibody detection. The sec-
ondary antibody was incubate for 40 min [27].
For both COX-2 and PD-L1 staining, following an incu-
bation with DAB substrate buffer and DAB chromogen, 
slides were counterstained on platform with hematoxy-
lin and rinsed in distilled water. Between all incubation 
steps, slides were extensively washed with bond wash 
solution. Then the slides were dehydrated out of platform 
in an ethanol series (30, 70, 100%) and four changes of 
100% xylene, and permanently sealed with automatic 
coverslips (DAKO #CS100). Each staining run contained 
positive and negative controls.
PD-L1 and COX-2 expression were reviewed and enu-
merated independently and blindly by two experienced 
pathologists (GB and AA) using a light microscopy. For 
each sample, at least five fields (inside the tumor and in 
the peripheral areas) and >500 cells were analysed. Using 
a semi-quantitative scoring system microscopically and 
referring to each protein scoring method in other stud-
ies, percentage of stained tumor cells in each lesion were 
evaluated for COX-2 and PD-L1 expression. Variations in 
the percentage of stained cells were within a 10% range 
for COX-2 expression. In consideration of the error, we 
evaluated the percentage of stained tumor cells at 10% 
intervals. Staining was graded as a semi-quantitative var-
iable ranged from 0 to 100% [28]. For PD-L1 expression 
variations in the percentage of stained cells were within 
a 1% range. Results were graded as negative (0+), light 
positive (1+) and positive (2+) when the PD-L1 score in 
an entire lesion was 0, 1–5, and >5% respectively [29, 30].
Immunofluorescence staining
Double-fluorescence staining of PD-L1 and COX-2 were 
conducted on a total of 12 representative FFPE tissue 
sections, 6 each from primary and metastatic lesions, 
including both positive and negative for PD-L1 (clone 
SP-142) or COX-2 (clone CX-294) at IHC staining. Fol-
lowing their deparaffinization and hydration, prepared 
slides were incubated with antigen retrieval in a pres-
sure cooker (Biocare) for 10 min at 110 °C. Following an 
incubation with protein blocking, slides were incubated 
with a cocktail of PD-L1- and COX-2-specific mAbs at 
RT. Primary antibodies were detected utilizing a cocktail 
of goat anti-mouse IgG dylight 488 and goat anti-rabbit 
IgG dylight 594. After washing for two times, nuclei were 
stained with DAPI at RT for 10 min, and stored at 4 °C. 
The slides were examined using a fluorescent microscope 
(Olympus BX61).
Cell lines
The BRAFV600E A375 and the NRASQ61R SK-MEL-2 mela-
noma cell lines were purchased from American Type 
Culture Collection (ATCC). All cell lines were cultured 
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in RPMI 1640 medium (HyClone Laboratories) sup-
plemented with 2  mmol/l l-glutamine (HyClone Labo-
ratories) and 10% fetal bovine serum (FBS) (HyClone 
Laboratories). All cells were cultured at 37  °C in a 5% 
CO2 atmosphere.
Cell proliferation and MTT assay
Cells were plated in triplicate in 96-well microtiter plates 
at the density of 3 × 103 per well in 100 μl of RPMI 1640 
medium supplemented with 10% FBS at 5% CO2 atmos-
phere and treated with celecoxib. Untreated cells were 
used as a control. Dimethyl sulfoxide (DMSO) (vehicle 
of the drug) concentration was maintained at 0.02% in 
all wells. Cell proliferation was evaluated at the indicated 
time point utilizing the MTT assay which was carried out 
as reported elsewhere [31]. Data are expressed as percent 
of proliferation of treated cells as compared to untreated 
control cells. All experiments were performed three inde-
pendent times in triplicates. The absorbance value at 
wavelength of 540 nm was determined using a microplate 
reader (Bio-Rad Laboratories).
Cell viability assay
Cells were seeded at the density of 4 × 105 in a 75 cm2 
tissue culture flask in RPMI 1640 medium supplemented 
with 10% FBS at 5% CO2 atmosphere and incubated with 
the indicated doses of celecoxib. Untreated cells were 
used as a control. The DMSO (vehicle of the drug) con-
centration was maintained at 0.02% in all flasks. Follow-
ing a 24 h incubation at 37 °C in a 5% CO2 atmosphere, 
cell viability was evaluated utilizing the trypan blue assay 
which was carried out as reported elsewhere [32].
Western blot analysis
Cells were seeded at the density of 4 × 105 in a 75 cm2 
tissue culture flask in RPMI 1640 medium supplemented 
with 10% FBS at 5% CO2 atmosphere and incubated with 
the indicated doses of celecoxib. Untreated cells were 
used as a control. The DMSO (vehicle of the drug) con-
centration was maintained at 0.02% in all flasks. Follow-
ing a 24 h incubation at 37 °C in a 5% CO2 atmosphere, 
cells were collected and lysed in lysis buffer [10 mM Tris-
HCl (pH 8.2), 1% NP40, 1 mM EDTA, 0.1% BSA, 150 mM 
NaCl] containing 1/50 (vol/vol) of protease inhibitor 
cocktail (Calbiochem). Western blot assay for signal-
ing-related proteins was carried out as described [33]. 
Immunoreactive bands were quantified using the image 
analysis tool ImageJ.
Flow cytometry analysis
Cells were seeded at the density of 4 × 105 in a 75 cm2 
tissue culture flask in RPMI 1640 medium supplemented 
with 10% FBS at 5% CO2 atmosphere and incubated with 
the indicated doses of celecoxib. Untreated cells were 
used as a control. The DMSO (vehicle of the drug) con-
centration was maintained at 0.02% in all flasks. Follow-
ing a 24 h incubation at 37 °C in a 5% CO2 atmosphere, 
cells were collected and cell surface stained as described 
[34]. Stained cells were analyzed with a flow cytometer 
(BD FACSAria II, BD Bioacience). Data were analyzed 
using Kaluza Flow Cytometry Analysis v1.3 software 
(Beckman Coulter).
Statistical analysis
Averages, standard deviations  (SD), and unpaired t test 
were calculated using MS-Excel. Data are shown as 
mean ± SD of the results obtained in at least three inde-
pendent experiments. Statistical analysis was performed 
with the Stata Statistical Software, Release 13 (Stata-
Corp LP, College Station, TX). Correlation of COX-2 and 
PD-L1 expression was analyzed by Spearman’s rank cor-
relation coefficient. Difference in the expression of COX-2 
in according to PD-L1 groups was analyzed using the 
Kruskal–Wallis rank test. Correlation of PD-L1 expres-
sion with pathological features of the tumor samples was 
analyzed by Fisher exact test. Differences in the expres-
sion levels of COX-2 and pathological features of tumors 
was analyzed using the Mann–Whitney U-test. Differ-
ence in COX-2 or PD-L1 expression in primary and not 
matched metastatic lesion groups were analyzed using the 
Mann–Whitney U test. P < 0.05 was considered to be sta-
tistically significant. All tests used were two-tailed.
Results
Tumor specimens
Forty-four samples obtained from patients who under-
went surgical resection of their primary melanoma 
tumors at our institution were analyzed. Table  1 sum-
marizes the tumor pathologic characteristics. Tumor 
thickness ranged from 0.5 to 10 mm (mean 2.92 ± 2.25). 
Table 1 Tumor pathologic characteristics of primary mela-
nomas
# (%)
Tumor thickness
 Range 0.50–10.00 mm
 Mean 2.92 ± 2.25 mm
Ulceration
 Absent 15 (34.1)
 Present 29 (65.9)
Tumor size
 pT1 6 (13.6)
 pT2 14 (31.8)
 pT3 11 (25.0)
 pT4 13 (29.6)
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Ulceration was present in 29 (65.9%) of the 44 primary 
melanoma tumors analyzed. Six (13.6%), 14 (31.8%), 
11 (25.0%) and 13 (29.6%) of the 44 primary melanoma 
tumors were T1, T2, T3 and T4, respectively. BRAF 
(V600E and V600K) and NRAS (Q61R and Q61L) muta-
tions were detected in 65.9 and 6.8%, respectively, of the 
primary melanoma tumor biopsies. No mutations in 
BRAF and NRAS were detected in the remaining 27.3% 
of the tumors (Additional file  1: Table S1). In addition, 
forty-five samples obtained from not matched metastatic 
lymph node biopsies were analyzed. BRAF (V600E and 
V600K) and NRAS (Q61R and Q61L) mutations were 
detected in 57.8 and 8.9%, respectively, of the meta-
static melanoma tumor biopsies. No mutations in BRAF 
and NRAS were detected in the remaining 33.3% of the 
tumors (Additional file 1: Table S2).
PD‑L1 expression in primary and not matched metastatic 
melanoma tissues and its correlation with the pathological 
features of tumors analyzed
PD-L1 positive cancer cells showed a membrane immune 
reactivity (Fig. 1). PD-L1 by cancer cells was expressed in 
55/89 cases (61.8%) of all tumor analyzed. Melanoma cells 
expressed PD-L1 in 32 (72.7%) and 23 (51.1%) of primary 
melanoma and not matched metastatic lesions, respec-
tively. In the primary lesions the staining was scored 
as negative, light positive and positive in 12 (27.3%), 22 
(50.0%) and 10 (22.7%) of the 44 lesions, respectively. In 
the metastatic lesions the staining was scored as nega-
tive, light positive and positive in 22 (48.9%), 7 (15.5%) 
and 16 (35.6%) of the 45 lesions, respectively. Statistical 
analysis demonstrated a significantly lower number of 
PD-L1 negative lesions in primary tumors as compared 
to not matched metastatic lesions (Mann–Whitney U 
test, P = 0.002).
No correlation was identified between PD-L1 expres-
sion on melanoma cells and the presence of ulceration 
and the T stage of the primary melanoma lesions. In 
addition no correlation was identified between PD-L1 
expression on melanoma cells and the BRAF/NRAS gen-
otype of the lesions analyzed.
COX‑2 expression in primary and not matched metastatic 
melanoma tissues and its correlation with the pathological 
features of tumors analyzed
COX-2-positive cells showed brownish granules in the 
cytoplasm (Fig. 2). COX-2 by cancer cells was expressed 
in 82/89 (92.1%) cases of all tumor analyzed. COX-2 
expression was negative on melanoma cells in 2 out of 44 
primary melanomas and 5 out of 45 metastatic lesions. In 
both primary and not matched metastatic lesions COX-2 
expression in melanoma cells ranged from 0 to 80%. 
Fig. 1 Representative IHC staining patterns with PD-L1-specific mAb (clone SP-142) of FFPE primary (a, b, c) and metastatic lymph node (d, e, f) 
from a total of 44 primary and 45 not matched metastatic melanoma tumors. PD-L1 expression was reviewed and enumerated independently and 
blindly by two experienced pathologists (GB and AA). PD-L1 expression was scored as negative (0+) (a, d), light positive (1+) (b, e) and positive 
(2+) (c, f) when the PD-L1 score in an entire lesion was 0, 1–5, and >5% respectively. Magnification is indicated. Arrows indicate examples of PD-L1 
positive melanoma cells
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The mean expression of COX-2 in primary tumors was 
43.8 ± 23.4% while it was 38.0 ± 23.2% in the metastatic 
lesions. No significant difference was found in COX-2 
expression between primary and not matched metastatic 
melanoma lesions. No correlation was identified between 
COX-2 expression in melanoma cells and the presence 
of ulceration or the T stage of the primary melanoma 
lesions. In addition no correlation was identified between 
COX-2 expression in melanoma cells and the BRAF/
NRAS genotype of the lesions analyzed.
PD‑L1 and COX‑2 correlation in primary and metastatic 
melanoma tissues
PD-L1 expression significantly correlated with COX-2 
expression in the melanoma lesions analyzed (Kruskal–
Wallis rank test, P  =  0.0008). Specifically, a significant 
correlation between COX-2 expression and PD-L1 
was found in both primary (Kruskal–Wallis rank test, 
P  =  0.001) and not matched metastatic (Kruskal–Wal-
lis rank test, P  =  0.048) lesions. PD-L1 was expressed 
in a greater extent in melanoma tissues which express a 
higher level of COX-2 (Spearman’s rank correlation coef-
ficient, spearman rho: +0.4376, P =  0.0001). The mean 
expression of COX-2 was 27.9 ± 20.0%, 45.2 ± 22.2% and 
60.0 ±  18.8% in primary melanoma lesions which were 
scored for PD-L1 as negative, light positive and positive, 
respectively (Fig. 3a). The mean expression of COX-2 was 
30.9 ±  23.0%, 35.7 ±  21.4% and 48.7 ±  21.2% in meta-
static melanoma lesions which were scored for PD-L1 as 
negative, light positive and positive, respectively (Fig. 3b).
PD‑L1 and COX‑2 co‑localize in primary and not matched 
metastatic melanoma tissues
We then investigated whether single melanoma cells 
expressing PD-L1 were also co-expressing COX-2. A 
double-immunofluorescence staining utilizing 12 repre-
sentative lesions, six each from primary and not matched 
metastatic melanomas, was performed. Representative 
staining patterns of primary and metastatic melanoma 
lesions with both PD-L1- and COX-2-specific mAbs are 
shown in Fig. 4. In all 12 melanoma tissue sections ana-
lyzed from both primary and not matched metastatic 
lesions the majority of cancer cells which express PD-L1 
also co-expressed COX-2 while most of the cells which 
did not express PD-L1 did not express COX-2.
COX‑2 inhibition down‑regulates PD‑L1 expression in both 
BRAF and NRAS mutant melanoma cell lines
We lastly investigated whether PD-L1 expression 
was modulated by COX-2 activity by testing PD-L1 
expression following inhibition of COX-2. The human 
BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma 
Fig. 2 Representative IHC staining patterns with COX-2-specific mAb (clone CX-294) of FFPE primary (a, b, c) and metastatic lymph node (d, e, f) 
from a total of 44 primary and 45 not matched metastatic melanoma tumors. COX-2 expression was reviewed and enumerated independently and 
blindly by two experienced pathologists (GB and AA). COX-2 expression was scored as variations in the percentage of stained cells at 10% intervals. 
Staining was graded as a semi-quantitative variable. Results ranged from 0 to 80% of positive melanoma cells. Percentage of COX-2 positive cells, 
tumor margin (dotted line) and magnification are indicated. Arrows indicate examples of COX-2 positive melanoma cells
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cell lines were used as an in vitro model. A375 and SK-
MEL-2 were treated with the selective COX-2 inhibitor 
celecoxib at different doses. As shown in Fig. 5a, follow-
ing a 24 h incubation, celecoxib inhibited the growth of 
both A375 and SK-MEL-2 melanoma cell lines in a dose-
dependent manner. The dose of 60  μM inhibited the 
growth of A375 and SK-MEL-2 melanoma cells of about 
50%. This effect was associated with induction of cell 
death and prevention of cell proliferation in both A375 
and SK-MEL-2 cells (Fig. 5b). The induction of cell death 
was more marked in A375 cell line than in SK-MEL-2 
cells. Based on these findings, we treated A375 and SK-
MEL-2 cells with 60 μM of COX-2 inhibitor and analyzed 
the expression of PD-L1. Both western blot (unpaired 
t test, P  <  0.001) and flow cytometry (unpaired t test, 
P  <  0.02) analyses demonstrated that treatment with 
celecoxib significantly down-regulated the total protein 
level and surface expression of PD-L1 in both A375 and 
SK-MEL-2 melanoma cells as compared to untreated 
cells (Fig. 6). 
Discussion
Targeting the immune checkpoint molecules CTLA-4, 
PD-1 and PD-L1 is completely revolutionizing the treat-
ment of advanced melanoma. Several clinical trials have 
convincingly shown that immune checkpoint inhibitors 
increase the overall survival of metastatic melanoma 
patients with or without BRAF/NRAS mutations [2–6]. 
Fig. 3 Correlation between PD-L1 and COX-2 expression in primary (a) and metastatic lymph node (b) of melanoma tumors. COX-2 expression, 
graded as a semi-quantitative variable, was correlated with PD-L1 expression scored as negative (0+), light positive (1+) and positive (2+) when the 
PD-L1 score in an entire lesion was 0, 1–5, and >5% respectively. Difference in the expression of COX-2 in according to PD-L1 groups was analyzed 
using the Kruskal–Wallis rank test. On each box, the central mark is the median, the edges of the box are the 25th and 75th percentiles, the whiskers 
extend to the most extreme data points not considered outliers, and outliers are plotted individually. P value is indicated
Fig. 4 Representative IHC (a, b, f, g) and matched immunofluorescent staining (c, d, e, h, i, l) patterns of FFPE primary (a, b, c, d, e) and not 
matched metastatic lymph node (f, g, h, i, l) of melanoma tumors with COX-2-specific mAb (clone CX-294) (a, c, f, h), PD-L1-specific mAb (clone 
SP-142) (b, d, g, i) and both COX-2- (clone CX-294) and PD-L1-specific mAbs (clone SP-142) (e, l). Immunofluorescent staining matches to squared 
field of IHC staining. COX-2 was detected by goat anti-mouse IgG dylight 488 (green). Immunofluorescent staining of PD-L1 was detected by goat 
anti-rabbit IgG dylight 594 (red). Nuclei were stained by DAPI (blue). Negative controls are provided in Additional file 1: Figure S1. Arrows indicate 
examples of positive cells. Tumor margin (dotted line) and magnification are indicated
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However the response rate of these novel immunothera-
peutic approaches is about 40–60%. A growing body of 
evidence indicates that a major obstacle to the success 
of immunotherapy is represented by the development 
of escape mechanisms utilized by tumor cells to avoid 
recognition and destruction by the host’s immune sys-
tem. The PD-1/PD-L1 axis represents one of the major 
mechanisms of tumor immune escape since expression 
of PD-L1 on cancer cells through the interaction with 
PD-1 on T cells inhibits the recognition and destruction 
of cancer cells by the host immune response.
So far PD-L1 expression by cancer cells correlates with 
melanoma progression. Furthermore PD-L1 expres-
sion by cancer cells is currently investigated as a poten-
tial biomarker in order to predict clinical responses to 
anti-PD-1 and -PD-L1 based immunotherapy in several 
malignancies [35]. In addition a higher expression of 
PD-L1 in tumors appears to predict for a higher clinical 
response rate in patients treated with anti-PD-1/PD-L1 
based immunotherapy as compared to patients which 
carry tumors that did not express PD-L1. Nevertheless, 
some patients not expressing PD-L1 in their tumors 
also benefit from PD-1/PD-L1 based immunotherapy 
[36]. These findings might reflect the dynamic expres-
sion of PD-1/PD-L1 by both cancer cells and immune 
cells. Indeed PD-1/PD-L1 expression can be induced on 
immune cells and cancer cells by the presence of soluble 
factors or cytokines present in tumor microenvironment. 
The latter are induced by the interaction of cancer cells 
with host immune cells during treatment with anti-PD-1/
Fig. 5 Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 
melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. 
Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incuba-
tion at 37 °C in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD 
of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments 
performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and 
NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 
μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incu-
bation at 37 °C in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable 
(negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001
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PD-L1 mAbs. In addition PD-1/PD-L1 expression can 
be induced by pro-tumorigenic pathways which are 
activated in cancer cells during cancer progression [14]. 
In this study we showed a relationship between COX-2 
and PD-L1 expression in melanoma cells. COX-2 is an 
important key survival molecule, currently investigated 
as a molecular marker and a potential tumor therapeutic 
target. In fact, the prophylactic use of COX-2 inhibitors 
such as acetylsalicylic acid has been shown to decrease 
the incidence of several cancers. In particular, its syner-
gistic activity with other anti-tumoral treatments, such 
as chemotherapy and radiotherapy [37–39] or with other 
molecular targets related to tumor growth and prolifera-
tion, including VEGFR or aromatase inhibitors [40–42] 
has been often highlighted. In their recent published 
work Markosyan et  al. [22] describe a cause effect rela-
tionship between COX-2 and PD-L1 expression in breast 
cancer cells. In addition Prima et al. describe that COX-2 
and the PGE2 pathway regulates PD-L1 expression in 
tumor-associated macrophages and myeloid-derived 
suppressor cells [43]. Our data in melanoma cells are in 
line with these findings since COX-2 is significantly asso-
ciated with PD-L1 in melanoma tumors and its inhibition 
by the COX-2 inhibitor celecoxib down-regulates the 
expression of PD-L1 in vitro. There is no clear evidence 
in the literature of the mechanisms which might under-
lie the effect on PD-L1 by COX-2. Some works reported 
a relationship between COX-2 and activation of AKT/
STAT3 or NF-κB pathways [44, 45] which are known 
to regulate PD-L1 expression [46–49]. However further 
studies are warranted to determine the underlying mech-
anisms. Future studies addressing the molecular signals 
that regulate PD-L1 surface expression by COX-2 in can-
cer cells might shed light on developing novel therapeutic 
agents to modulate cancer cell immune responses.
COX-2 isoform is shown to be up-regulated during 
both inflammation and cancer [16, 19]. In melanoma 
COX-2 is shown to be expressed in both primary and 
metastatic lesions and its expression correlates with 
pathological features of primary tumors and patient’s 
prognosis [28, 50, 51]. Our data are in line with previous 
reports since COX-2 by cancer cells in melanoma tumors 
is found to be highly expressed in both primary and not 
matched metastatic melanoma lesions although no sig-
nificant correlation between COX-2 and the pathologi-
cal features of tumor analyzed was found. These findings 
may reflect the low number of lesions analyzed as well as 
the selection of the tumors.
Fig. 6 Down-regulation of PD-L1 by celecoxib in BRAFV600E and NRASQ61R melanoma cell lines. BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma 
cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used 
as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. a Following a 24 h incubation at 37 °C in a 5% CO2 
atmosphere, cells were harvested and lysed. Cell lysates were analyzed by western blot with the indicated mAbs. PD-L1 was detected using the 
PD-L1-specific mAb (clone SP-142). GAPDH was used as a loading control. Representative results are shown (upper panel). The levels of PD-L1 nor-
malized to GAPDH are plotted and expressed as mean ± SD of the results obtained in three independent experiments (bottom panel). *** indicate 
P < 0.001. b Following a 24 h incubation at 37 °C in a 5% CO2 atmosphere, cells were harvested and cell surface stained with the PE-conjugated 
PD-L1-specific mouse mAb [clone MIH1 (RUO)]. PE-conjugated mouse IgG1 was used as a specificity control. Representative results are shown
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A body of evidence indicates a role for COX-2 in the 
development/modulation of different steps of cancer 
progression and several mechanisms may underlie this 
pro-tumorigenic activity of COX-2 including (i) pro-
duction of reactive oxygen species responsible for DNA 
damage, (ii) aberrant activation of intracellular pathways 
such as MAPK and the PI3  K/AKT pathways, (iii) acti-
vation of STAT3, (iv) induction of Bcl-2 family members 
and (v) production of growth factors including epidermal 
growth factor (EGF) and fibroblast growth factor (FGF) 
[16]. These in turn favor the increase rate of mutations, 
the proliferation, pro-survival signals and initiated tumor 
cells by determining an imbalance between cell prolifera-
tion and cell death stimuli. Our data demonstrated that 
COX-2 is involved in the proliferation of melanoma cells 
since treatment of melanoma cells with or without BRAF/
NRAS mutations with the COX-2 inhibitor celecoxib 
inhibits their proliferation and induces cell death. This 
effect are in line with previous work [21, 52, 53], pro-
viding COX-2 inhibition as an additional valid option in 
order to inhibit melanoma cell progression. The molecu-
lar mechanisms underlying this anti-tumor activity of 
celecoxib in melanoma cells was not fully investigated 
in the present study. In A375 cell line inhibition of cell 
proliferation and/or induction of cell death by celecoxib 
was associated with down-regulation of Bcl-2. These data 
are line with previous works which have reported that 
Bcl-2 down-regulation by COX-2 inhibition is mediated 
by NF-kB [45]. In contrast in SK-MEL-2 cell line treat-
ment with celecoxib did not change the expression of 
Bcl-2 which results to be not expressed (Additional file 1: 
Figure S2). Further studies are needed to clarify the mol-
ecules which are involved in inducing cell death and/or 
preventing cell proliferation following treatment with 
COX-2 inhibitor in this cell line.
Lastly COX-2 is shown to contribute to immune eva-
sion and resistance to cancer immunotherapy in several 
cancer types including breast, lung, colon cancer and 
melanoma [22, 52, 54–57]. COX-2 has been involved in 
suppressing the activity of immune cells including den-
dritic cells, natural killer and T cells as well as in pro-
moting type-2 immunity which causes tumor immune 
evasion. In the present work the activity of COX-2 and its 
inhibition on immune cell activation/proliferation and/or 
on the interaction between immune cells and melanoma 
cells was not investigated. However the novel informa-
tion we show is that in melanoma cells COX-2 activ-
ity causes tumor immune escape by modulating PD-L1 
expression. Indeed COX-2 is found to be co-expressed 
to PD-L1 in both primary and not matched metastatic 
lesions and inhibition of COX-2 by celecoxib down-reg-
ulates PD-L1 in melanoma cells. The latter plays a major 
role in inhibiting the host immune response.
Conclusions
Over the past years the possibility to combine different 
therapies, such as biological therapy and immunotherapy, 
has contributed to completely change the setting of treat-
ment plans [58]. The limited duration of the response 
obtained with BRAF and MEK inhibition in BRAFV600 
melanoma and the impressive durability but the relatively 
low response rate obtained with the block of the immune 
checkpoint molecules proved to be surprising. Several 
clinical trials are examining the combinations of different 
immune checkpoint inhibitors as well as the combination 
of immune checkpoint inhibitors with the small mol-
ecule inhibitors [59–62]. In this view our data shown that 
COX-2 expression correlates with and modulates PD-L1 
expression in melanoma cells. Besides modulating PD-L1 
expression, COX-2 is also shown to be involved in mela-
noma progression since its inhibition induces cell death 
and prevents cell proliferation. These findings have clini-
cal relevance since they provide a rationale to implement 
novel clinical trials to test COX-2 inhibition as a potential 
treatment to prevent melanoma progression and immune 
evasion as well as to enhance the anti-tumor activity of 
PD-1/PD-L1 based immunotherapy for the treatment 
of melanoma patients with or without BRAF/NRAS 
mutations.
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